Clinical Trial Update: CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study of CPI-613 (devimistat) in combination with bendamustine for relapsed/refractory T-cell non-Hodgkin lymphoma has been terminated with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• T-cell Non-hodgkin Lymphoma

Drugs mentioned

• CPI-613 (devimistat) (devimistat)
• Treanda (bendamustine) (bendamustine)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2025-05-02